Five Prime Therapeutics
San Francisco
About Five Prime Therapeutics
FivePrime is discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant proteins in the human body to find the best protein for treatment of a given clinical indication. FivePrime’s ProScreen Engine enables the rapid production and screening of all therapeutically relevant proteins in medically-focused assays at the highest quality standards in the industry. This powerful approach is the polar opposite of the industry’s traditional “one protein at a time”. The ProScreen Engine comprises the definitive protein collection and screening process for biologics discovery and is unprecedented in its efficiency, quality, and scale. In addition to DBL Investors, investors include Domain Associates, Versant Ventures, Kleiner Perkins Caufield and Byers, Texas Pacific Group, HealthCap, and Advanced Technology Ventures.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $345.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2018)
- Ticker: nasdaq:FPRX
- Website: fiveprime.com
- Phone: 415-365-5600
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/five-prime-therapeutics-133078 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.